Aixcrypto Holdings, INC. (AIXC) — 8-K Filings

All 8-K filings from Aixcrypto Holdings, INC.. Browse 37 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (37)

8-K Filing — Dec 16, 2025
AIxCrypto Holdings Files 8-K with Financials — Nov 21, 2025 Risk: low
AIxCrypto Holdings, Inc. (formerly Qualigen Therapeutics, Inc. and RITTER PHARMACEUTICALS INC) filed an 8-K on November 21, 2025, reporting events as of Novembe
8-K Filing — Nov 20, 2025
Qualigen Therapeutics Files 8-K with Corporate Updates — Nov 17, 2025 Risk: low
Qualigen Therapeutics, Inc. filed an 8-K on November 17, 2025, reporting events that occurred on November 12, 2025. The filing indicates amendments to its Artic
Qualigen Therapeutics Changes Auditors to BDO USA — Oct 7, 2025 Risk: medium
Qualigen Therapeutics, Inc. announced on October 1, 2025, a change in its independent registered public accounting firm. The company dismissed Marcum LLP and ha
Qualigen Therapeutics Files 8-K with Material Agreements — Oct 3, 2025 Risk: medium
On September 29, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
Qualigen Therapeutics Files 8-K on Officer/Director Changes — Sep 29, 2025 Risk: low
Qualigen Therapeutics, Inc. filed an 8-K on September 26, 2025, reporting on the departure of directors or certain officers, the election of directors, the appo
Qualigen Therapeutics Files 8-K — Sep 25, 2025 Risk: medium
On September 19, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
Qualigen Therapeutics Files 8-K for Material Agreement — Sep 16, 2025 Risk: medium
On September 15, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement, likely a financing or debt arrangement, as indicated by the fil
Qualigen Therapeutics Faces Delisting Notice — Sep 8, 2025 Risk: high
Qualigen Therapeutics, Inc. filed an 8-K on September 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's pri
Qualigen Therapeutics Enters Material Definitive Agreement — Aug 27, 2025 Risk: medium
On August 21, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly know
Qualigen Therapeutics Files 8-K with Key Agreements and Equity Sales — Jul 28, 2025 Risk: medium
On July 28, 2025, Qualigen Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engage
Qualigen Therapeutics Files 8-K — Jul 16, 2025 Risk: low
On July 16, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Qualigen Therapeutics Announces Board and Executive Changes — Jun 24, 2025 Risk: medium
Qualigen Therapeutics, Inc. announced on June 20, 2025, a series of significant corporate actions. These include the election of new directors, the appointment
Qualigen Therapeutics Faces Delisting Concerns — May 19, 2025 Risk: high
Qualigen Therapeutics, Inc. filed an 8-K on May 19, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing indicates p
Qualigen Therapeutics Faces Delisting Concerns — May 1, 2025 Risk: high
Qualigen Therapeutics, Inc. filed an 8-K on April 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerl
Qualigen Therapeutics Files 8-K Report — Jan 28, 2025 Risk: low
On January 28, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation
Qualigen Therapeutics Files 8-K: Security Holder Rights Modified — Dec 26, 2024 Risk: medium
Qualigen Therapeutics, Inc. announced on December 23, 2024, a material modification to the rights of its security holders. The company also filed financial stat
Qualigen Therapeutics Announces Board and Executive Changes — Nov 13, 2024 Risk: medium
Qualigen Therapeutics, Inc. announced on November 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the de
Qualigen Therapeutics Files 8-K on Security Holder Rights — Nov 8, 2024 Risk: medium
On November 5, 2024, Qualigen Therapeutics, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles o
Qualigen Therapeutics Relocates Principal Executive Offices — Nov 1, 2024 Risk: low
Qualigen Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a change in its principal executive offices to 5857 Owens Avenue, Suite 300, Carlsbad, C
Qualigen Therapeutics Files 8-K on Shareholder Vote Matters — Oct 29, 2024 Risk: low
Qualigen Therapeutics, Inc. filed an 8-K on October 29, 2024, reporting on matters submitted to a vote of security holders as of October 25, 2024. The filing in
Qualigen Therapeutics Faces Nasdaq Delisting Warning — Oct 22, 2024 Risk: high
Qualigen Therapeutics, Inc. received a notification on October 18, 2024, indicating it is not in compliance with Nasdaq's minimum bid price requirement. The com
Qualigen Therapeutics Appoints New Chief Medical Officer — Oct 9, 2024 Risk: low
On October 3, 2024, Qualigen Therapeutics, Inc. announced the appointment of Dr. Paul E. M. Mann as Chief Medical Officer. Dr. Mann brings extensive experience
Qualigen Therapeutics Board Changes Announced — Sep 26, 2024 Risk: medium
Qualigen Therapeutics, Inc. announced on September 23, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new
Qualigen Therapeutics Files 8-K — Sep 20, 2024 Risk: low
On September 20, 2024, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhi
Qualigen Therapeutics Enters Material Definitive Agreement — Sep 9, 2024 Risk: medium
Qualigen Therapeutics, Inc. announced on September 6, 2024, that it entered into a material definitive agreement. The company, formerly known as Ritter Pharmace
Qualigen Therapeutics Files 8-K — Sep 5, 2024 Risk: low
Qualigen Therapeutics, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The filing details the company's corporate struc
Qualigen Therapeutics Faces Nasdaq Delisting Warning — Aug 5, 2024 Risk: high
Qualigen Therapeutics, Inc. received a notification on August 2, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on t
Qualigen Therapeutics Files 8-K: Material Definitive Agreement — Jul 18, 2024 Risk: medium
On July 12, 2024, Qualigen Therapeutics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, it
Qualigen Therapeutics Secures $10M Loan from Innoviva — Jul 15, 2024 Risk: medium
On July 12, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement, a loan and security agreement with Innoviva, Inc. for a $10 million
Qualigen Therapeutics Announces Change of Control and Executive Changes — Jul 11, 2024 Risk: medium
On July 5, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement related to a change in control of the company. The filing also announc
Qualigen Therapeutics Faces Delisting Concerns — May 30, 2024 Risk: high
Qualigen Therapeutics, Inc. filed an 8-K on May 30, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principa
Qualigen Therapeutics Files 8-K on Agreements and Equity Sales — Apr 16, 2024 Risk: medium
On April 11, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the fili
Qualigen Therapeutics Terminates Material Definitive Agreement — Mar 28, 2024 Risk: medium
Qualigen Therapeutics, Inc. announced on March 25, 2024, the termination of a material definitive agreement. The company, formerly known as Ritter Pharmaceutica
Qualigen Reports Multiple Corporate Actions: Agreements, Debt, Equity Sales, and Officer Changes — Feb 27, 2024 Risk: medium
Qualigen Therapeutics, Inc. filed an 8-K on February 27, 2024, reporting multiple significant events that occurred on February 25, 2024. These events include th
Qualigen Therapeutics Enters Material Definitive Agreement — Feb 22, 2024 Risk: medium
Qualigen Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 15, 2024. The filing indicates an "Entry into a Mate

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX